Emerging Therapies For Dmd

•Als PPT, PDF herunterladen•

0 gefällt mir•400 views

truthofe

[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Weitere ähnliche Inhalte

Was ist angesagt?

Antisense oligonucleotide therapy

ROHIT

Antisense technologies and antisense oligonucleotides

RangnathChikane

Treatment for lysosomal storage diseases using crispr cas9

limchloe

Epigenetic regulation of cardiogenesis

Pasteur_Tunis

DOOR syndrome

Satrupa Das

1506.full

Elsa von Licy

Bio 1

BioinformaticsInstitute

Bortezomib as standard of care for multiple myeloma

spa718

Plegable

SaraOcampo

Austin Transplantation Sciences is an open access, peer reviewed, scholarly journal dedicated to publish articles covering all areas of Transplantation Sciences. The journal aims to promote research communications and provide a forum for doctors, researchers, physicians and healthcare professionals to find most recent advances in all areas of Transplantation Sciences. Austin Transplantation Sciences accepts original research articles, reviews, mini reviews, case reports and rapid communication covering all aspects of Transplantation Sciences. Austin Transplantation Sciences strongly supports the scientific up gradation and fortification in related scientific research community by enhancing access to peer reviewed scientific literary works. Austin Publishing Group brings universally peer reviewed journals under one roof thereby promoting knowledge sharing, mutual promotion of multidisciplinary science.

Austin Transplantation Sciences

Austin Publishing Group

JC paper-2009

Nisha Rizvi

NAGLU_IGF2 ERT in mouse

Shih-hsin Kan

ANTISENSE OLIGONUCLEOTIDES

ayanarkumar19

DNA methylation

Sahar Sajadian

11 orlowski lunch-symposium_final

spa718

hinckley poster5 (2)

Sj Afshari

Viral in hemat

Joydeep Ghosh

molecular markers in muscular dystrophy

Malar Malar

Esnrt poster cd20

FarragBahbah

Medullary thyroid carcinoma

SoM

Was ist angesagt? (20)

Antisense oligonucleotide therapy

Antisense technologies and antisense oligonucleotides

Treatment for lysosomal storage diseases using crispr cas9

Epigenetic regulation of cardiogenesis

DOOR syndrome

1506.full

Bio 1

Bortezomib as standard of care for multiple myeloma

Plegable

Austin Transplantation Sciences

JC paper-2009

NAGLU_IGF2 ERT in mouse

ANTISENSE OLIGONUCLEOTIDES

DNA methylation

11 orlowski lunch-symposium_final

hinckley poster5 (2)

Viral in hemat

molecular markers in muscular dystrophy

Esnrt poster cd20

Medullary thyroid carcinoma

Andere mochten auch

Work Place Giving

Save Our Sons Taylor

Session 17 kate_bushby

EURORDIS - Rare Diseases Europe

Swot

Tubamubashira

Idea mapping

Tubamubashira

Rare disease stakeholder dynamics pmrg institute fall 2014

azdybak

Medicine is at heart a narrative activity–the telling and receiving of story. The patient interview is based on the notion that the patient, as story-teller, will share his or her experience, and that the doctor, as active listener, will be able to take that story and make sense of it in the world of science and medicine. Health care is supposed to build on the story with each contact, but if we don’t know the story, each contact becomes a closed episode of its own, disconnected from every other episode. Fragmentation results as the outcome of a nonstoried approach to health care. In this workshop, we will explore how the ancient art of storytelling can foster an empathetic healthcare model and generate a framework for a more holistic approach to treating the patient, while at the same time providing a rich source of diagnostic clues. Narrative medicine represents a storied understanding of health. It’s a return to listening to the patient’s story. Doctors who are trained to listen to the story of the disease need to learn to listen also to the story of the illness. We’ll explore how to incorporate narrative medicine and storytelling into medical education

Teaching the Rx Narrative; Story as Medicine

Marie Ennis-O'Connor

Andere mochten auch (6)

Work Place Giving

Session 17 kate_bushby

Swot

Idea mapping

Rare disease stakeholder dynamics pmrg institute fall 2014

Teaching the Rx Narrative; Story as Medicine

Ähnlich wie Emerging Therapies For Dmd

cancer nice paper.pdf

asthabisht789

Tuberous Sclerosis - Orrin Devinsky, MD

NYU FACES

Cerullo_verona2010_AdenovirusGT

Vincenzo Cerullo

Access to Research Date 11-08-2018 Venue Conference HAll NIAS IISc campus Conference and workshops for clinical practitioners to introduce them to modern tools and an alternative approach to modern scientific research. Purpose 1. Build a network of physicians across the country 2 Train physicians to analyse clinical data and restructure it to make it compatible with research standards 3. Introduce modern tools to understand the mechanism of actions of medicine 4. Introduce artificial intelligence and machine learning to clinical practitioners to support decision-making processes Access to Science Clinical experience and traditional knowledge are important sources of data that affect decision making processes in modern healthcare systems. This data should be made accessible for scientific evaluation and validation to improve healthcare worldwide. The Open Source Pharma Foundation believes that clinical practitioners from various disciplines should have the right to access research so that they can help identify problems, contribute their scientific knowledge, and support the discovery ecosystem. Background The majority of medical practitioners working on the ground level with patients do not take part in open clinical research worldwide. However, the data collected and owned by them plays an important role in establishing better discovery pathways. Through this workshop, we seek to open opportunities to enhance health care systems around the world and to overcome the following challenges faced by medical practitioners. 1. Regulatory limitations 2. Academic limitations 3. Time constraints 4. Lack of access to modern tools 5. Lack of access to research facilities

Open Source Pharma /Genomics and clinical practice / Prof Hosur

opensourcepharmafound

nihms336576

Wan Lu Woo

P53 apoptosis

Anfal Izaldeen AL KATEEB

news and views

Maria Teresa Esposito

Sindrome di rett

iva martini

Oncogene1.PDF

Alexandre "Sasha" Nesterov

1.2 fpr

EURORDIS Rare Diseases Europe

Antisense therapy

konatham teja kumar reddy

Seminario biologia molecular- Maria Upegui

isabellabuitrago4

TBI is the leading cause of death among young adults and children in the developed world, accounting for over 50,000 deaths per year. [12] TBI results in a sleuth of poor health outcomes, including hemorrhaging, seizures, neural edema, neural inflammation, and cognitive and emotional disabilities. All of these outcomes are a direct result of fundamental degradation of the BBB over a time course post TBI. [1] [12] The BBB is an integral structure that forms around the microvascular of the cerebral cavity. Endothelial cells form the basal membrane through which strictly controlled movement of molecules is observed between the extravascular and intravascular space across this basal membrane. This basal membrane is maintained by endothelial cells, having tight junctions between them to make up the pores through which transport of molecules can occur between the brain and microvasculature. These tight junctions are maintained through cross-talk between the endothelial cells and supporting neurons such as astrocytes and pericytes. [2] A multitude of proteins make up the tight junctions between the endothelial cells, including six main scaffolding structures Claudins 1, 3, and 5, ZO-1, Occludins, and Cadherins. [3] VEGF release following trauma induces endothelial cells to release matrix metalloproteinases (MMPs), in particular MMP9, which can catalyze the N-terminal amino acids that compose the tight junction protein ZO-1. [10] [11] MMP9 when in circulation is also known to activate tumor necrosis factor alpha (TNFɑ) which in turn upregulates transcription of MMP9, creating a positive feedback loop. [11] The management of MMP production is three fold, transcription, proenzyme activation, and substrate inhibition. [11] In our study, it is proenzyme activation via TP that is the focus and how that affects the overall transcription levels of the tight junction proteins within the endothelial cells and astrocytes.

Endothelial Cell Mediated Delay of Blood Brain Barrier Recovery Following Tra...

Arthur Stem

Seminario biomol 2

therong

Symposium Presentation-Change in Transcriptome in Human Cells Deficient and P...

MSc dissertation

Gene Therapyrr

Bordet-JPET-2007

Functional analysis of proteomic biomarkers and targeting glioblastoma stem c...